Animal Medicine Market Report 2026

The animal medicine market size has grown strongly in recent years. It will grow from $53.76 billion in 2025 to $57.16 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing prevalence of animal diseases, growth of companion and livestock animal populations, advancements in veterinary pharmaceuticals, rising awareness of animal nutrition and health, expansion of veterinary services networks.

The animal medicine market size is expected to see strong growth in the next few years. It will grow to $73.34 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising demand for nutraceutical feed additives, technological innovations in veterinary drug formulations, increasing adoption of precision medicine for animals, growth in online veterinary medicine distribution, government initiatives to support animal health and disease prevention. Major trends in the forecast period include rising use of veterinary pharmaceuticals for companion and livestock animals, increasing adoption of feed additives to improve animal nutrition, growing preference for otc and prescription-based medicines, expansion of oral and parenteral administration routes, rising distribution through veterinary services and online channels.

The rising rates of pet ownership and adoption are expected to drive the growth of the animal medicine market in the coming years. Pet ownership refers to the responsibility of an individual or household for the care, well-being, and management of a domesticated animal and represents a long-term legal and ethical commitment. The increase in pet ownership is fueled by growing awareness of the emotional and health benefits associated with pets, as individuals seek companionship, stress reduction, and improved overall well-being through pet care. The animal medicine market supports this trend, as a growing pet population increases demand for medications that promote animal health, prevent diseases, and support overall well-being. For example, in March 2025, the American Pet Products Association, a US-based non-profit organization, reported that 94 million US households owned at least one pet, compared with 82 million households in 2023. Therefore, the increasing rates of pet ownership and adoption are contributing to the expansion of the animal medicine market.

Leading players operating in the animal medicine market are focusing on developing innovative offerings, such as Food and Drug Administration (FDA)-approved generic veterinary drugs for chronic conditions including urinary incontinence and heart failure, to improve affordability and accessibility of essential long-term treatments for pets and their owners. An FDA-approved generic veterinary drug is a bioequivalent alternative to a previously approved brand-name medication that provides the same safety and clinical effectiveness at a lower cost. For instance, in September 2025, ZyVet Animal Health Inc., a US-based supplier of affordable generic animal pharmaceuticals, introduced the first FDA-approved generic phenylpropanolamine hydrochloride tablets for the management of canine urinary incontinence, along with a generic formulation of furosemide tablets used to treat congestive heart failure and fluid retention in dogs and cats. These products are available in multiple strengths to support accurate dosing and deliver consistent clinical performance, offering veterinarians cost-effective treatment options that enhance long-term adherence and broaden access to established therapies previously constrained by brand-name pricing.

In July 2024, Merck Animal Health, a U.S.-based company, acquired Elanco Animal Health Inc. This acquisition enhances Merck Animal Health’s position in the aqua industry by adopting a comprehensive approach to promoting fish health, welfare, and sustainability in aquaculture, conservation, and fisheries. Merck intends to leverage this acquisition to offer a wide range of solutions for both warm and cold-water species, including vaccines, anti-parasitic treatments, and nutritional supplements. Elanco Animal Health Incorporated is also a U.S.-based company.

Major companies operating in the animal medicine market are Zoetis, Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Elanco Animal Health Incorporated, Virbac Group, Ceva Santé Animale, Phibro Animal Health Corporation, China Animal Husbandry Industry Co. Ltd, Vetoquinol S.A., Neogen Corporation, Century Pharmaceuticals Limited, Cargill India Pvt. Ltd., Intervet Australia Pty Ltd, Jurox Pty Ltd, SeQuent Scientific Ltd, Guangdong Wens Dahuanong Biotechnology Co. Ltd, Shandong Lukang, Bayer Animal Health Cadila Pharmaceuticals Ltd., Koninklijke DSM n.v, Nutreco N.V., SaluVet GmbH, Interfeed, Biotex Plus Ltd., Cymedica, Vet Resolution, Vetruus Ltd, Nimrod Veterinary Products Ltd., Bimeda, Animalcare, IDT Biologika, Vetiquinol S.A, UCBVET, Biowet Puławy, Pasteur Romania, Vector-Vita-LLC, NITA-FARM, Bioveta, Heska, Dechra Veterinary Products, IDEXX Laboratories, Agrodan CA, Agrovet Market S.A, Invesbio S.A, Sauvet, Vetanco, ALKE SAGLIK URUNLERI San. ve Tic. A.S., MISTAV Ilac ve Tavukculuk San.Tic.Ltd, Kahmavet, Lemavet, ASVET, Ekinos - Veterinary Products, Lanrex Pharmaceuticals Nig Ltd.

North America was the largest region in the animal medicine market in 2025. Asia-Pacific was the second-largest region in the animal medicine market. The regions covered in the animal medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal medicine market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs have impacted the animal medicine market by raising costs for imported veterinary pharmaceuticals, feed additives, and active ingredients, affecting companion animal and livestock medicine segments in regions such as North America, Europe, and Asia-Pacific. OTC and prescription medicines are particularly affected due to import dependencies. While tariffs increase operational costs, they also encourage local production of veterinary drugs and feed additives, fostering regional manufacturing capabilities and reducing dependency on imports.

The animal medicine market research report is one of a series of new reports that provides animal medicine market statistics, including animal medicine industry global market size, regional shares, competitors with a animal medicine market share, detailed animal medicine market segments, market trends and opportunities, and any further data you may need to thrive in the animal medicine industry. This animal medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal medicines encompass a comprehensive category of drugs and therapies, comprising veterinary vaccines, veterinary antibiotics, and other pharmaceuticals specifically designed to address and treat diseases in animals. These medications play a crucial role in enhancing animal performance and health by identifying disease symptoms and administering appropriate drugs for the cure of illnesses.

The primary categories of animal medicines include veterinary pharmaceuticals and feed additives, catering to both livestock and companion animals. Veterinary pharmaceuticals represent medications administered to animals for the treatment of various diseases. These animal medicines are distributed and utilized by various entities such as veterinary hospitals, pharmacies, drug stores, and veterinary clinics, contributing to the overall health and well-being of animals.

The animal medicine market consists of sales of procuring drugs to shield against external parasites such as fleas, ticks, and heartworms (intestinal parasites). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.